Association of Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Hallym University Medical Center.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Hallym University Medical Center
Information provided by (Responsible Party):
Hallym University Medical Center
ClinicalTrials.gov Identifier:
NCT01233986
First received: October 21, 2010
Last updated: October 4, 2011
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate whether the serum apoB48 level is associated with atherosclerotic ischemic stroke.
| Condition |
|---|
|
Acute Ischemic Stroke |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Prospective, Matched Case Control, Multicenter, Observational Study for the Association of Serum Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS) |
Resource links provided by NLM:
Further study details as provided by Hallym University Medical Center:
Primary Outcome Measures:
- The serum level of fasting apolipoprotein B-48 [ Time Frame: 72 hours within stroke onset ] [ Designated as safety issue: No ]
- The serum level of postprandial apolipoprotein B-48 [ Time Frame: within 72 hours after stroke onset ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- The serum level of the postprandial triglyceride [ Time Frame: 72 hours within stroke onset ] [ Designated as safety issue: No ]
- The serum level of fasting total cholesterol [ Time Frame: within 72 hours after stroke onset ] [ Designated as safety issue: No ]
- The serum level of fasting LDL cholesterol [ Time Frame: within 72 hours after stroke onset ] [ Designated as safety issue: No ]
- the level of fasting HDL cholesterol [ Time Frame: within 72 hours after stroke onset ] [ Designated as safety issue: No ]
- the level of fasting triglyceride [ Time Frame: within 72 hours after stroke onset ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Serum level of apolipoprotein B-48
| Estimated Enrollment: | 112 |
| Study Start Date: | May 2010 |
| Estimated Study Completion Date: | October 2011 |
| Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Case group - Large artery atherosclerosis |
| Control group-Small vessel occlusion |
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Tertiary Hospital
Criteria
Inclusion Criteria:
Large artery atherosclerotic ischemic stroke group(LAA group)
- Age over 20 years
- Patients with symptomatic stenosis in the eligible vessels(the middle cerebral artery, anterior cerebral artery, or internal carotid artery) as assessed by MRA or CTA corresponding to the acute ischemic stroke
- Patients without the occlusion of corresponding artery by MRA or CTA
- The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke
Small vessel occlusive ischemic stroke group (SVO group)
- Age over 20 years
- Patients with acute ischemic stroke of basal ganglia, internal capsule, or corona radiata
- Patients without both symptomatic and asymptomatic arterial occlusion or stenosis by MRA or CTA
- Patients without a history of systemic atherosclerosis(for example, acute myocardial infarction, angina, peripheral arterial disease, aortic aneurysm)
- The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke
Exclusion Criteria: both LAA group and SVO group
- Patients with cardioembolic ischemic stroke
- Patients treated with lipid lowering agents or steroid within the previous 30 dsys
- Patients with severe liver disease (AST >100 or ALT >100) at the time of randomization
- Patients with endocrine disease except diabetes mellitus at the time of randomization (for example, thyroid disease, adrenal disease)
- Patients with severe renal disease (serum creatinine >2.0mg/dl)at the time of randomization
- chronic alcoholics or drug user
- Patients with infection at the time of randomization
- Patients, in the opinion of the investigator, unlikely to comply with the clinical study or unsuitable for the any other disease or reason
- Informed consent has not been obtained
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01233986
Contacts
| Contact: Byung-Chul Lee, MD, PhD | +82-31-380-3741 | ssbrain@hallym.ac.kr |
| Contact: Kyung-Ho Yu, MD, PhD | +82-31-380-3743 | ykh1030@hallym.ac.kr |
Locations
| Korea, Republic of | |
| Hallym University Sacred Heart Hospital | Recruiting |
| Anyang, Korea, Republic of | |
| Contact: Byung-chul Lee, MD,PhD +82-31-380-3741 ssbrain@hallym.ac.kr | |
| Contact: Kyung-Ho Yu, MD, PhD +82-31-380-3743 ykh1030@hallym.ac.kr | |
| Sub-Investigator: Mi Sun Oh, MD | |
Sponsors and Collaborators
Hallym University Medical Center
Investigators
| Principal Investigator: | Byung-Chul Lee, MD,PhD | Hallym University Medical Center |
More Information
No publications provided
| Responsible Party: | Hallym University Medical Center |
| ClinicalTrials.gov Identifier: | NCT01233986 History of Changes |
| Other Study ID Numbers: | ABYSS |
| Study First Received: | October 21, 2010 |
| Last Updated: | October 4, 2011 |
| Health Authority: | South Korea: Institutional Review Board |
Keywords provided by Hallym University Medical Center:
|
Acute Ischemic Stroke Atherosclerosis Apolipoprotein B48 |
Additional relevant MeSH terms:
|
Ischemia Stroke Cerebral Infarction Pathologic Processes Cerebrovascular Disorders Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Brain Infarction Brain Ischemia |
ClinicalTrials.gov processed this record on May 19, 2013